Clinical trials: Streptococcus Pneumoniae Infections
Pneumococcal Infections
Pneumococcal Reference Standard
Serum 89 SF is a supply of serum that was collected from people who were vaccinated with the pneumococcal vaccine in the late 1980s. The supply of this serum is running low.
- Trial name
- NCT00479323
- Testing
- Pneumovax 23
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Pneumococcal
Study of Gamma PN3 in the Elderly
Phase 1 double- blind randomised active comparator dose escalating study of Gamma PN3 in the elderly
- Trial name
- NCT06562790
- Testing
- Gamma PN3, Prevnar
- Where
- Australia
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- GPN Vaccines
Pneumonia, Pneumococcal Infections
Humoral Determinants of Immunity to Pneumococcal Infection
The purpose of this study is to determine whether there are differences in the level of antibody to capsular polysaccharides of S.
- Conditions
- Pneumonia, Pneumococcal Infections, Infections, Streptococcus Pneumoniae
- Trial name
- NCT00304382
- Testing
- Prevnar, Pneumovax
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- VA Office of Research and Development
Bronchiolitis
Study of Pneumococcal Carriage in RSV Bronchiolitis in Infants Aged 6 to 18 Months
The relationship between RSV (human respiratory syncytial virus) infections and invasive infections or pneumonia caused by Streptococcus pneumoniae has been observed epidemiologically for several years.
- Trial name
- Synergy (NCT06722716)
- Testing
- Swab collection
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Infections, Streptococcal, Streptococcus Pneumoniae Vaccines
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection
The purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals' 10Pn-PD-DiT vaccine in children aged between 2 and 17 years of age having asplenia, splenic dysfunction or complement…
- Trial name
- NCT01746108
- Testing
- Synflorix™
- Where
- 6 sites in Poland, Russia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rubella, Mumps
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first…
- Conditions
- Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
- Trial name
- NCT00861744
- Testing
- GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 1,259 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Otitis Media, Otitis Media With Effusion
Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media
The aim of this study is to assess in France the impact of Prevenar on the possible evolution of the pneumococcal serotypes distribution and antibiotic resistance in NP samples of children with AOM.
- Conditions
- Otitis Media, Otitis Media With Effusion, Pneumococcal Infections
- Trial name
- NCT00195611
- Testing
- Prevenar
- Where
- 35 sites in France
- Volunteers
- 3,293 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Infections, Streptococcal
Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule
This is a booster study in 2 groups of healthy children less than 3 years old to measure the reactogenicity, safety and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine, when given as a booster or as a two-dose…
- Trial name
- NCT00513409
- Testing
- Synflorix, Infanrix Hexa, Havrix
- Where
- Chile
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection, Lung Parenchyma
Inventory of the Management of Acute Community-acquired Pneumonia in Strasbourg University Hospitals
Acute community-acquired pneumonia (CAP) refers to an acute infection of the lung parenchyma, occurring within the first 48 hours of hospitalization. It is a frequent, serious pathology with a strong economic impact.
- Trial name
- PPAC (NCT05661513)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Strasbourg, France
Pneumococcal Pneumonia, Influenza
The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine
The immunogenicity of simultaneous administration of quadrivalent influenza vaccine and pneumococcal vaccine was unknown. The purpose of present study is to compare the immunogenicity of simultaneous administration of influenza…
- Trial name
- NCT02592486
- Testing
- Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®, Sequential administration of Pneumovax NP® and Fluvic HA syringe®
- Where
- Japan
- Volunteers
- 162 people
- Sponsor
- Kameda Medical Center
COVID-19, Pneumococcal Infections
Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years
Vaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults aged over 60 or 65 years (depending local guidelines) who have never received a pneumococcal vaccine or…
- Trial name
- NVX_PCV20 (NCT05767606)
- Testing
- NVX, PCV20
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Pneumococcal Infectious Disease
Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
A phase II clinical trial of a 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older.
- Trial name
- NCT06678620
- Testing
- Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, Reinovax PCV24 formulation 3
- Where
- 2 sites in China
- Volunteers
- 992 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Streptococcus Pneumoniae Infection
Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants
This study is a phase III clinical trial to evaluate the immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (multivalent conjugate) in infants aged 2 months (at least 6 weeks) and 3 months.
- Trial name
- NCT05759520
- Testing
- 13-valent pneumococcal conjugate vaccine (multivalent conjugate), Prevenar 13
- Where
- 5 sites in China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Fosun Adgenvax Biopharmaceutical Co.,Ltd.
Infections, Streptococcal
Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants
The purpose of this study is to assess the immunogenicity, reactogenicity and safety of two formulations of GSK Biologicals' pneumococcal vaccine (2830929A and 2830930A) administered as 3-dose primary vaccination during the first…
- Trial name
- NCT01616459
- Testing
- Pneumococcal conjugate vaccine GSK2830929A, Pneumococcal conjugate vaccine GSK2830930A, Synflorix™
- Where
- 42 sites in Czechia, Germany and 2 more
- Volunteers
- 953 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
This study will evaluate the safety, reactogenicity and immunogenicity of a booster dose of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™ given at 12-18 mo of age to children primed with either…
- Trial name
- NCT00370396
- Testing
- Synflorix, Prevenar, Infanrix hexa
- Where
- 35 sites in Finland, France and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia, Respiratory Tract Diseases
Clinical Trial of Recombinant Pneumococcal Protein Vaccine
Streptococcus pneumoniae infections often cause serious health problems, especially in infants and the elderly. Failure to cover all polysaccharide types of vaccines is a greater problem for adults than for children.
- Conditions
- Pneumonia, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT05622942
- Testing
- PBPV, PPV23
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Streptococcal Pneumonia, HIV/AIDS
Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults
HIV-infected patients are 30- to 100-fold more susceptible to invasive pneumococcal diseases. Pneumococcal vaccination is the best way to decrease the large pneumococcal disease burden, but the optimal timing of vaccination is…
- Trial name
- NCT03838497
- Testing
- Prevenar13
- Volunteers
- 70 people
- Sponsor
- Korea University Guro Hospital
Infections, Streptococcal
A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants
The primary aim of the study is to demonstrate that an investigational 4-dose presentation of the 10Pn-PD-DiT vaccine with preservative is non-inferior to the licensed presentation of Synflorix (preservative-free) in terms of…
- Trial name
- NCT02447432
- Testing
- Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation), Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation), DTPw-HBV/Hib
- Where
- Bangladesh
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infectious Diseases
Baby Vaccine Study (Sched3)
This multicentre, parallel group, block randomised clinical trial aims to investigate the post booster antibody response in UK infants given a reduced priming schedule of meningococcal serogroup B vaccine and 13 valent…
- Trial name
- NCT02482636
- Testing
- DTaP/IPV/Hib vaccine, 13 valent Pneumococcal Conjugate Vaccine, Rotavirus vaccine
- Where
- United Kingdom
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Infections, Streptococcal, Streptococcus Pneumoniae Vaccines
Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine
Evaluate the immune response of GSK Biologicals' 10-valent pneumococcal conjugate vaccine one month after completion of a 3-dose primary vaccination course administered at 2, 3, 4 months of age
- Trial name
- NCT00307541
- Testing
- Pneumococcal (vaccine)
- Where
- 32 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline